Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF1α/STAT3/NF-κB signaling pathway

Ethnopharmacological relevance: Modified Biejia Jianwan (M-BJJW), a Traditional Chinese Medicine (TCM) decoction, has exhibited great potential in treating hepatocellular carcinoma (HCC). However, its underlying functional mechanism still remains unknown.Aim of the study: The study aimed to explore the anti-hepatocarcinogenic effects of M-BJJW, specifically its influence on PD-L1-mediated immune evasion in hypoxic conditions, and elucidate the related molecular mechanisms in HCC.Materials and methods: To investigate the therapeutic efficacy and mechanisms underlying M-BJJW's effects on HCC, we employed a diethylnitrosamine (DEN)-induced rat model maintained for 120 days. Following model establishment, flow cytometry was utilized to assess the distribution of immune cell populations in peripheral blood, spleens, and tumor tissues after M-BJJW administration. Simultaneously, enzyme-linked immunosorbent assays (ELISA) were conducted to analyze cytokine profiles in serum samples. Immunohistochemistry was employed to determine the expression levels of crucial proteins within tumor tissues. Furthermore, HCC cells exposed to CoCl2 underwent Western blot analysis to validate the expression levels of HIF-1 alpha, PD-L1, STAT3, and nuclear factor kappa B (NF-kappa B) p65. The modulatory effects of STAT3 and NF-kappa B p65 were investigated using specific inhibitors and activators in wild-type cell lines. High-performance liquid chromatography coupled with mass spectrometry (HPLC/MS) was utilized to identify the chemical constituents present in M-BJJW-medicated serum. The immunomodulatory properties and the anti-tumor activities of M-BJJW were evaluated by coculturing with peripheral blood mononuclear cells (PBMC) and the CCK-8 assay. Additionally, we assessed MBJJW's impact on hypoxia-induced alterations in HCC cell lines using immunofluorescence and Western blot assessments.Results: M-BJJW exhibited substantial therapeutic advantages by effectively alleviating pathological deterioration within the HCC microenvironment. In the DEN-induced rat model, M-BJJW administration notably reduced tumor growth. Flow cytometry analyses revealed an increased proportion of Cytotoxic T lymphocytes (CTLs) accompanied by a simultaneous decrease in regulatory T cells (Tregs). ELISA data supported a marked decrease in pro-inflammatory cytokines, including interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF-alpha). Immunohistochemistry confirmed the suppressive effect of M-BJJW on the expression of HIF-1 alpha and PDL1. Notably, western blotting unveiled the role of HIF-1 alpha in regulating PD-L1 expression via the STAT3 and NF kappa B signaling pathways in HCC cell lines, which was validated using activators and inhibitors of STAT3 and NF-kappa B. The CCK-8 assay and co-culture techniques demonstrated the anti-tumor activity of M-BJJW. Immunofluorescence and western blotting further confirmed that M-BJJW-containing serum dose-dependently inhibited HIF-1 alpha, PD-L1, p-STAT3, and p-p65 in hypoxic HCC cell lines.Conclusions: M-BJJW demonstrates significant therapeutic potential against HCC by influencing the hypoxic microenvironment, thereby regulating the immunosuppressive milieu. Specifically, M-BJJW modulates the HIF 1 alpha/STAT3/NF-kappa B signaling pathway, leading to reduced PD-L1 expression and an elevated ratio of cytotoxic T lymphocytes (CTLs), while concurrently decreasing T regulatory cells (Tregs) and immunosuppressive factors. These synergistic effects aid in countering PD-L1-mediated immune evasion, presenting compelling pharmaco-logical evidence supporting the clinical application of M-BJJW as a therapeutic approach for HCC.